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Abstract
AIM: To study the relation between collagen 1, α-smooth 
muscle actin (α-SMA) and CD34 expression and the 
most essential portoenterostomy (PE) outcomes.
METHODS: Liver specimens were obtained at PE from 
33 biliary atresia (BA) patients for immunohistochemical 
analysis of collagen 1, α-SMA and CD34. Liver biopsies 
from 35 organ donors were used as controls. Expres-
sion patterns were related to clinical data including age 
at PE, serum total and conjugated bilirubin concentra-
tion at the time of PE and during follow-up, incidence 
of esophageal varices in follow-up upper gastrointesti-
nal endoscopies, and native liver survival as well as to 
detailed histopathological findings.
RESULTS: Collagen 1 (16.4% vs 4.5%, P < 0.0001), 
α-SMA (17.9% vs 4.6%, P < 0.0001) and CD34 (4.9% 
vs 3.8%, P = 0.017) were markedly overexpressed in 
BA patients compared with controls. Patients who un-
derwent liver transplantation by age of two years had 
significantly higher expression of collagen 1 (18.6% 
vs 13.7%, P = 0.024), α-SMA (20.4% vs 15.4%, P = 
0.009) and CD34 (5.9% vs 4.0%, P = 0.029) at PE 
compared with native liver survivors. CD34-positive 
microvessels were identified in the centrizonal region 
close to central vein in every BA patient. In majority 
of BA cases (56%) neovascularization was frequent as 
CD34-positive microvessels were observed in over half 
of the hepatic lobules. In controls, the CD34-positive 
microvessels were rare as they were completely ab-
sent in 40 % and were found in less than 5 % of the 
hepatic lobules in the rest. The difference between BA 
patients and controls was significant (P < 0.0001). Pa-
tients who developed esophageal varices by two years 
had significantly higher expression of CD34 at PE com-
pared with patients without varices (5.6% vs 4.0%, P 
= 0.019). Expression of α-SMA (r  = 0.758, P < 0.0001) 
and collagen 1 (r  = 0.474, P = 0.016), and the amount 
of CD34-positive microvessels (r  = 0.356, P = 0.047) 
were related to patient age at PE.
CONCLUSION: Hepatic myofibroblastic cell activation, 
fibrogenesis and neovascularization are enhanced in 
BA, progress with increasing PE age and relate to native 
liver survival and development of esophageal varices.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: The majority of biliary atresia (BA) patients 
require liver transplantation (LTx) due to progressive 
hepatic fibrosis and associated portal hypertension. 
We aimed to relate expression of collagen 1, α-smooth 
muscle actin (α-SMA) and CD34 to the most essential 
portoenterostomy (PE) outcomes. Collagen 1, α-SMA 
and CD34 were markedly overexpressed in BA patients 
compared with controls and centrizonal neovasculariza-
tion was increased in BA. Patients who underwent LTx 
by age of two years had significantly higher expression 
of collagen 1, α-SMA and CD34 at PE compared with 
native liver survivors. Fibrogenesis and neovasculariza-
tion are enhanced in BA, progress with increasing PE 
age and relate to native liver survival and development 
of esophageal varices.
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INTRODUCTION
Biliary atresia (BA) is a rare cholestatic liver disease of  
infancy leading, if  untreated, to cirrhosis, liver failure and 
death within the first two years of  life[1]. Kasai portoen-
terostomy (PE) aims to re-establish bile flow and is con-
sidered the first line treatment of  BA[2]. However, BA still 
remains the most common indication for paediatric liver 
transplantation (LTx) due to progressive liver fibrosis and 
associated complications such as esophageal varices fol-
lowing PE[3]. 
Although the pathogenesis of  BA remains unclear, 
virus-induced fibroinflammatory process affecting the 
biliary tree is marked[4,5]. The process of  hepatic fibro-
genesis and development of  cirrhosis is multifactorial 
and multitude of  involving proteins has been identified[6]. 
In liver fibrosis extracellular matrix proteins, mainly col-
lagens accumulate excessively. Majority of  collagens 
are deposited by myofibroblasts that differentiate from 
hepatic stellate cells (HSCs) and portal fibroblasts[7,8]. In 
normal liver tissue HSCs are inconspicuous but upon ac-
tivation these cells transform into α-smooth muscle actin 
(α-SMA) producing contractile myofibroblastic cells[9]. In 
two previous studies with a smaller number of  patients, 
increased α-SMA expression was found to associate with 
histological fibrosis scores of  the liver and PE outcomes 
in infants with BA[10,11].
CD34 is a cell surface glycoprotein expressed in vas-
cular endothelium. The relationship between progressive 
fibrosis and angiogenesis is unclear but neovasculariza-
tion is found in a variety of  liver diseases. This vascular 
reorganization may represent a response to liver injury 
including alterations in liver microcirculation associated 
with portal hypertension and development of  esophageal 
varices[12,13].
In the present study we explored the hepatic expres-
sion of  collagen 1, α-SMA and CD34 at the time of  
PE in a controlled manner, and related the results to the 
most essential PE outcomes including clearance of  jaun-
dice, native liver survival and development of  esophageal 
varices.
MATERIALS AND METHODS
Patients and study design
This study was performed at the Children’s Hospital in 
Helsinki, Finland. The national paediatric LTx program 
has been running since 1987 in our hospital and the 
treatment of  BA was nationally centralized to our unit in 
2005[14]. All available perioperative liver biopsies obtained 
at the time of  PE were collected for immunohistological 
analysis and medical records were reviewed. A total of  33 
BA patients born between 1990 and 2012 were enrolled. 
Collected clinical data included age at PE, serum total 
and conjugated bilirubin concentration at the time of  PE 
and during follow-up, detection of  esophageal varices in 
follow-up upper gastrointestinal endoscopies, and indica-
tions as well as the age at LTx. All patients underwent 
endoscopic surveillance for esophageal varices as de-
scribed previously[15]. A multidisciplinary team (paediatric 
hepatologists, transplant paediatricians, paediatric gastro-
intestinal, and transplant surgeons, neurologists) decided 
on listing for liver transplantation based on the following 
parameters: (1) original liver disease, quality of  life (chol-
angitis and septic episodes), growth, nutrition, neurology, 
kidney function, bone health; (2) portal hypertension 
(portal flow, spleen size, hypersplenism, varices, ascites); 
(3) cholestasis (bilirubin, bile acid levels, itching); (4) liver 
biochemistry (ALT, AST, GT, clotting factors, prealbu-
min, albumin, cholesterol, Galactose half-life); (5) imaging 
findings (liver and spleen size, parenchymal heterogeneity, 
biliary lakes, focal lesions); and (6) liver histology (fibrosis, 
cirrhosis, bile ducts). Clearance of  jaundice was defined 
as a decrease in serum bilirubin concentration below 20 
µmol/L. As controls we examined 35 liver biopsies ob-
tained from deceased donors at organ recovery. 
The ethics committee of  the hospital district of  Hel-
sinki and Uusimaa approved this study a priori and the 
study conforms to the principles of  the 1975 Declaration 
of  Helsinki.
Immunohistochemistry and imaging
Altogether 33 biopsies were taken at the time of  Kasai 
PE, including 6 core needle biopsies and 27 surgical 
wedge biopsies. The biopsies were fixed in formalin, em-
bedded in paraffin, sliced, and stained with conventional 
stains. The representativeness of  the biopsy material was 
considered good: > 8 (wedge) or > 10 (needle) portal 
areas were present in 29 (88%) biopsies. Histological liver 
fibrosis was assessed by Metavir (0-4) and Ishak (0-6) 
fibrosis scores by two experienced pediatric liver patholo-
gists, blinded to the clinical patient data, until consensus 
was reached[16,17].
Immunostaining for collagen 1 was performed with 
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COL1A2/COL1A1 monoclonal antibody, clone I-8H5 
(Abnova Corporation, Taiwan), for α-SMA using Mono-
clonal Mouse Anti-Human Smooth Muscle Actin, clone 
1A4 (Dako, Denmark) and for CD34 using Monoclonal 
Mouse Anti-Human CD34 Class Ⅱ, clone QBEnd-10 
(Dako, Denmark) and NovoLink Polymer Detection Sys-
tem (Leica Biosystems Newcastle Ltd, Newcastle Upon 
Tyne, United Kingdom).
A Leica DM RXA microscope was used to obtain 
images of  stained sections. A total of  five random portal 
areas were chosen from each section of  wedge biopsies 
(× 100 magnification) and all core needle biopsies were 
photographed as a whole. The proportion of  the anti-
body-positive area (area fraction) was measured by using 
ImageJ Image Analysis Software[18]. To evaluate neovas-
cularization CD34-positive endothelial cell clusters form-
ing centrizonal microvessels were counted with semi-
quantitative scoring system. Each biopsy was reviewed 
and scored for the presence of  microvessels on scale of  
1-4 (Table 1). Imaging and all immunohistochemical ex-
pression analyses were performed without knowledge of  
the clinical patient data.
Statistical analysis
The data are reported as means and standard deviation 
or medians and range. Comparisons between groups 
were performed with Mann-Whitney U-test and multiple 
comparisons with Kruskal-Wallis test. Correlations were 
calculated with Spearman’s rank correlation. A P-value < 
0.05 was considered significant. All of  the analyses were 
made with Statview software (Statview 5.0.1; SAS Insti-
tute Inc., CA, United States). 
RESULTS
Patient characteristics
Table 2 illustrates the patient characteristics at the time 
of  PE. No type Ⅰ atresias were found and in four pa-
tients with type Ⅲ atresia perioperative cholangiography 
showed patent passage from gallbladder to bowel (type 
Ⅲa). The median (range) age at PE among all BA pa-
tients was 64 (7-141) days and median serum bilirubin at 
the time of  PE and at three months following PE was 
174 (98-470) μmol/L and 21 (2-627) μmol/L, respective-
ly. Of  the 33 patiens, 30 had been followed-up over two 
years. Overall, 58% (19/33) of  the patients cleared their 
jaundice and 57% (17/30) survived with their native liver 
beyond two years following PE. By two years after PE, 
47% (14/30) of  the patients had developed endoscopi-
cally verified esophageal varices.
Expression of collagen 1, α-SMA and CD34 in BA vs 
control livers
As shown in Figure 1, expression of  collagen 1, α-SMA 
and CD34 was markedly increased in BA when compared 
with controls (16.4% vs 4.5%, P < 0.0001, 17.9% vs 4.6%, 
P < 0.0001, 4.9% vs 3.8%, P = 0.017, respectively). The 
increase was most striking for collagen 1 and α-SMA, 
stained area fractions being about four fold higher than 
in controls. The portal tracts stained intensively with col-
lagen 1 and marked collagen 1 positive septae protruded 
towards the central vein. α-SMA staining showed strong 
immunoreactivity both on portal areas and along perisi-
nusoidal spaces. The expression of  collagen 1, α-SMA 
and CD34 did not differ significantly between different 
subtypes (Ⅱ, Ⅲ, Ⅲa) of  BA (P = 0.360, P = 0.345 and P 
= 0.736, respectively for collagen 1, α-SMA and CD34). 
Expression of collagen 1, α-SMA and CD34 in relation to 
clearance of jaundice, native liver survival and the age 
at the time of portoenterostomy 
Patients who underwent LTx by age of  two years showed 
significantly higher expression of  collagen 1, α-SMA and 
CD34 in liver biopsies obtained at PE when compared to 
patients who survived with their native livers beyond two 
years (Figure 2 and Table 3). Children who cleared their 
jaundice tended to have lower expression of  collagen 1 
and α-SMA at PE (Table 3), although this did not reach 
statistical significance, (P = 0.079 and P = 0.097, respec-
tively). The degree of  α-SMA staining correlated with 
the level of  preoperative conjugated bilirubin (r = 0.448, 
P = 0.023), bilirubin level at three months (r = 0.446, P 
= 0.029) and relative change of  bilirubin level by three 
months (r = -0.395, P = 0.044). Patients who underwent 
LTx by age of  two years were older at the time of  PE 
than native liver survivors, but the difference was not 
quite statistically significant (79.1 d vs 65.8 d, P = 0.054). 
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Data presented as median and range. Comparisons between groups 
were performed with Kruskal-Wallis test. BA: Biliary atresia; PE: 
Portoenterostomy. 
Table 2  Patient characteristics at the time of portoenteros-
tomy  
BA type n  (%) Age at PE (d) Bilirubin 
(μmol/L)
Conjugated 
bilirubin
Ⅱ 3 (9.1) 102 (78-141) 186 (98-247) 162 (86-207)
Ⅲ 26 (78.8) 64 (7-140) 172 (103-470) 117 (45-224)
Ⅲa   4 (12.1) 51 (37-81) 171 (103-201) 85 (69-109)
P = 0.092 P = 0.838 P = 0.183
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Table 1  Prevalence of centrizonal microvessels in biliary 
atresia patients (n  = 32) at the time of portoenterostomy 
and in control (n  = 35) livers
Number of patients BA Controls
Patients
Grade 1   0 14
Grade 2   5 21
Grade 3   9   0
Grade 4 18   0
P < 0.0001
Data presented as number of patients. Comparison between groups was 
performed with Mann-Whitney U-test. Microvessel grades: 1: No central 
zones with microvessels; 2: < 5% of central zones with microvessels; 3: 
5%-50% of central zones with microvessels; and 4: > 50% of central zones 
with microvessels. BA: Biliary atresia.
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Figure 1  Expression of collagen 1, α-smooth muscle actin and CD34 in biliary atresia vs control livers. Staining of collagen 1 (A, B), α-SMA (C, D) and CD34 (E, 
F) by immunohistochemistry. Figure A, C and E represent liver biopsies of a BA patient, who underwent Kasai portoenterostomy at the age of 54 d and figure B, D and 
F are liver biopsies obtained from a deceased donor (× 100 magnification). The same area of the histological tissue section is illustrated after immunohistochemistry 
for both subjects, respectively. Portal tracts (pt) stain intensively with collagen 1 and marked collagen 1 positive septaes (arrows) protrude towards central vein (cv) (A). 
In control liver collagen 1 staining is limited to portal area and endothelial lining of central vein (B). α-SMA staining shows strong immunoreactivity both in portal areas 
(pt) and along perisinusoidal spaces (arrows) (C), whereas in control specimen a faint α-SMA staining can be seen in biliary epithelial cells (D). Marked increase in 
CD34 staining is observed on portal (arrow) and centrizonal (arrowhead) area on liver biopsy of BA patient (E) compared with control (F). Summary of collagen 1 (G), 
α-SMA (H) and CD34 (I) immunohistochemistry in BA patients and controls. Collagen 1, α-SMA and CD34 were markedly overexpressed in BA at the time of Kasai 
portoenterostomy compared with controls. The results are expressed as proportion of the antibody-positive area. The box represents interquartile range, line across 
the box median, and the whiskers 90th percentile range. α-SMA: α-smooth muscle actin; BA: Biliary atresia.
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The age at the time of  PE correlated positively with the 
expression of  α-SMA (r = 0.758, P < 0.0001) (Figure 
3), collagen 1 (r = 0.474, P = 0.016), and the amount of  
CD34-positive microvessels (r = 0.356, P = 0.047).
Neovascularization and CD34 immunohistochemistry in 
relation to esophageal varices
Patients who developed esophageal varices by two years 
following PE had significantly higher expression of  
CD34 at the time of  PE compared with patients who re-
mained free of  varices (Table 3). Of  note, expression of  
collagen 1 or α-SMA were not associated with develop-
ment of  esophageal varices.
CD34-positive microvessels were identified in the 
centrizonal region close to central vein in every BA pa-
tient. In 18 BA cases (56%) neovascularization was fre-
quent as CD34-positive microvessels were observed in 
over half  of  the hepatic lobules. In controls, the CD34-
positive microvessels were rare as they were absent in 40 
% and were found in less than 5 % of  the hepatic lobules 
in the rest (Figure 4 and Table 1). The difference between 
BA patients and controls was significant (P < 0.0001). 
The amount of  CD34-positive microvessels did not dif-
fer significantly between different subtypes (Ⅱ, Ⅲ, Ⅲa) 
of  BA (P = 0.426). 
Interrelations between collagen 1, α-SMA and CD34 and 
correlations with histological fibrosis scores
Expression of  α-SMA was closely related with the ex-
pression of  collagen 1 (r = 0.731, P = 0.0002). It also 
correlated positively with CD34 (r = 0.502, P = 0.011) 
expression and histological fibrosis scores (Metavir and 
Ishak, r = 0.515, P = 0.010 and r = 0.511, P = 0.011, re-
spectively). Collagen 1 expression correlated with fibrosis 
scores (Metavir and Ishak, r = 0.503, P = 0.012 and r = 
0.513, P = 0.010, respectively) and CD34 expression (r = 
0.625, P = 0.0014).
DISCUSSION
Early diagnosis and successful PE establishing sufficient 
bile flow are the key events for extended native liver sur-
vival in BA[1]. Even though the majority of  BA patients 
end up with LTx due to progressive hepatic fibrosis and 
associated portal hypertension it is essential to increase 
the proportion of  BA patients, who survive with their 
own liver into adolescence or even adulthood. LTx carries 
well-known risks of  allograft ageing and the side effects 
of  long-term immunosuppression[19]. Several cytokines 
have been identified to play an important role in the regu-
lation of  liver fibrogenesis. Transforming growth factor 
β1 (TGF-β1) is one of  the most powerful profibrotic 
cytokines and the family of  matrix metalloproteases is 
recognized as another key mediator in this process[20,21]. 
Despite intensive research, understanding of  mechanisms 
that regulate disease progression following PE is scarce. 
Several candidate genes have been proposed to act as a 
prognostic markers when predicting outcomes[22,23], but 
further understanding of  pathogenesis of  BA is critical 
concerning development of  more effective treatment 
strategies.
Hepatic stellate cells have a crucial role in the patho-
genesis of  hepatic fibrosis. After transformation into 
myofibroblasts in response to a liver injury, stellate cells 
start to produce increased amounts of  collagen and ex-
press an intracellular microfilament protein α-SMA, a 
marker of  activated HSC phenotype[24]. Increased α-SMA 
expression has been shown to associate with increased 
liver fibrosis as assessed by histological scoring and PE 
outcomes in infants with BA[11,25]. We found a 4-fold 
increase in α-SMA and collagen 1 expression in BA pa-
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Figure 2  Comparison of collagen 1 (A), α-smooth muscle actin (B) and 
CD34 (C) staining by immunohistochemistry between patients, who 
received liver transplant by two years of age and native liver survivors. 
The results are expressed as proportion of the antibody-positive area. All of the 
studied proteins were overexpressed at the time of Kasai portoenterostomy in 
patients, who were transplanted by two years. The box represents interquartile 
range, line across the box median, and the whiskers 90th percentile range. NL: 
Native liver; LT: Liver transplant; α-SMA: α-smooth muscle actin. 
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tients compared with controls. Overexpression of  α-SMA 
staining was related to clearance of  jaundice as it corre-
lated with serum bilirubin concentration and relative de-
crease of  bilirubin three months after PE. Patients who 
survived with their native liver for the first two years had 
significantly lower expression of  α-SMA and collagen 
1 at the time of  PE than patients who underwent LTx. 
Those who underwent LTx were older at the time of  PE 
and, although the age difference was not quite statisti-
cally significant, it accords well with the improved clinical 
outcomes of  PE performed at early age[26]. Furthermore, 
age at PE had a strong positive correlation with the ex-
pression of  α-SMA and collagen 1. Collectively, these 
findings suggest that myofibroblastic cell activation as-
sociated liver fibrosis progresses with advancing age after 
birth before PE, being a major predictor of  native liver 
survival. 
Besides activated stellate cells, portal myofibroblasts 
are another cell type expressing α-SMA, and similarly 
to the present study, increase in α-SMA expression 
around portal tracts has been previously shown to occur 
in BA[27]. Here, an intense increase in α-SMA staining 
was observed also in perisinusoidal spaces in addition 
to portal regions. Although definitive source of  α-SMA 
expressing cells can not be ascertained by immunohisto-
chemistry alone, it seems likely that these cells originated 
from portal myofibroblasts and activated stellate cells. As 
expected, expression pattern of  accumulating collagen 1 
followed that of  α-SMA expressing myofibroblastic cells 
producing extracellular matrix proteins[7]. 
CD34 is a glycoprotein expressed on vascular en-
dothelium and CD34 immunostaining can be used to 
elucidate neovascularization in response to a liver in-
jury[11,12]. We assessed neoangiogenesis by CD34 staining 
using both quantitative and qualitative approaches. The 
degree of  CD34 staining was significantly increased in 
BA patients compared with controls when measured as 
an immunopositive area on histological liver sections. 
We then analysed centrizonal areas in hepatic lobules to 
explore possible neovascularization in the region around 
the central vein, theoretically most prone to ischemic in-
jury. Only distinct CD34-positive endothelial cell clusters 
with a vessel lumen were considered as microvessels to 
avoid misinterpretation of  faint diffuse sinusoidal expres-
sion of  CD34 as revascularization. Microvessels around 
the central vein were more frequent among BA patients 
compared with controls, which is a novel finding in BA. 
Interestingly, patients who developed endoscopically veri-
fied esophageal varices during follow-up had significantly 
higher expression level of  CD34 already at the time of  
PE compared to those who did not. Regarding pathogen-
esis of  esophageal varices, myofibroblastic differentation 
of  portal fibroblasts and HSC activation lead to increased 
hepatic vascular resistance by accumulation of  extracel-
lular matrix proteins, but also dynamic changes in hepatic 
vasculature occuring in chronic liver injury are important 
as evidenced by activation of  the renin-angiotensin sys-
tem[28]. Experimental studies on portal hypertension and 
liver cirrhosis further imply that not only altered hemo-
dynamics but also active neovascularization contributes 
to formation of  collateral vessels and that hypoxia and 
angiogenesis progress along with fibrogenesis in response 
to chronic liver injury[29,30]. Hepatopulmonary syndrome 
(HPS) represents an important cause of  pulmonary dis-
ease in children with BA. Corresponding animal models 
suggest involvement of  pulmonary neovascularization 
and activation of  angiogenic signalling pathways also in 
HPS[31].
Data presented as mean and SD. Comparisons between groups were performed with Mann-Whitney U-test. BA: Biliary atresia; PE: Portoenterostomy; NL: 
Native liver; LT: Liver transplant; α-SMA: α-smooth muscle actin. 
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Figure 3  Correlation between the age at the time of portoenterostomy and 
α-smooth muscle actin expression. A significant correlation was seen using 
Spearman’s rank correlation test (r = 0.758, P < 0.0001). α-SMA: α-smooth 
muscle actin; PE: Portoenterostomy.
Table 3  Hepatic expression of collagen 1, α-smooth muscle actin and CD34 in biliary atresia (n  = 27) at the time of portoenter-
ostomy and in control (n  = 35) livers
Clearance of jaundice 2-yr native liver survival Esophageal varices All BA patients Controls
Yes No NL LT Yes No
Collagen 1 14.7 (4.9) 18.5 (5.4) 13.7 (3.5) 18.6 (5.4) 17.2 (4.9) 14.6 (5.0) 16.4 (5.4) 4.5 (2.2)
Area, % (SD)  P = 0.079 P = 0.024  P = 0.217  P < 0.0001
α-SMA 16.4 (5.1) 19.8 (4.8) 15.4 (4.9) 20.4 (4.2) 18.2 (4.3) 17.1 (6.1) 17.9 (5.2) 4.6 (1.9) 
Area, % (SD) P = 0.097 P = 0.009 P = 0.537 P < 0.0001
CD34   4.4 (1.4)   5.6 (2.4)   4.0 (0.9)   5.9 (2.4)   5.6 (2.0)   4.0 (1.6)   4.9 (2.0) 3.8 (1.0)
Area, % P = 0.213  P = 0.029  P = 0.019 P = 0.017
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This study has certain limitations such as the relatively 
small number of  patients. It is also impossible to obtain 
liver biopsies from matched healthy infants. However, 
considering rarity of  BA and current literature our series 
of  33 BA patients is reasonably good in size. 
In conclusion, hepatic expression of  α-SMA, collagen 
1 and CD34 was increased in BA, suggesting myofibro-
blastic cell activation associated fibrogenesis and neovas-
cularization. Low expression of  α-SMA and collagen 1 
at the time of  PE was related to improved bile flow and 
native liver survival. Microvessels were common in the 
centrizonal region of  the hepatic lobules among BA pa-
tients already at the time of  PE and increased expression 
of  CD34 predicted development of  esophageal varices. 
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